Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel ther...
Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline ...
Brain Cancer Canada is pleased to award $68,000 for an innovative research initiative led by Dr. Aru Narendran, MD, PhD, and Dr. Patrick Sipila, PhD, at ...
Enabled by WuXi Biologics' industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to ...
Fujirebio announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/&beta...
National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (tra...
Invisalign® Palatal Expanders offer doctors a removeable, safe, and clinically effective alternative to traditional palatal expanders. With Invi...
The Asthma and Allergy Foundation of America (AAFA) appreciates the President’s Executive Order calling attention to America’s persistent pro...
Angelini Ventures joins top-tier investor syndicate Investment will fund Phase 1b studies evaluating Therini Bio’s lead candidate, THN391, for ...
Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, announced that its collaboration par...
ANPD001 was well tolerated with no major safety issues in low-dose cohort Patients showed early improvements in patient-reported and clinician-re...
To mark Bladder Cancer Awareness Month this May, bladder health brand Jude has conducted new research into how much charitable funding is allocat...
Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS...
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases, toda...
© 2025 Biopharma Boardroom. All Rights Reserved.
